Gapping up
In reaction to strong earnings/guidance: LEN +3.2%, EHIC +2%, MKC +1.3%
M&A news: ADMP +25.2% (to acquire privately held US Compounding; expected to close in the second quarter of 2016), YHOO +0.5% (wants a deadline of April 11 for bids, according to WSJ)
Other news: KERX +19.8% (announces positive top-line results from phase 3 study of ferric citrate for the treatment of iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease), CNL +13.2% (receives regulatory clearance for sale of co), OHRP +10.5% (reaches agreement on the Special Protocol Assessment with the FDA on the design of the Phase III trial for drug candidate squalamine lactate ophthalmic solution), GALE +8.5% (clinical trial with Neuvax achieves 70 qualifying disease free survival events), OREX +8% (in sympathy with other biotechs this morning), MNOV +4.7% (cont vol pre-mkt), BLRX +4.2% (announces 'positive' top-line results from BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia), NQ +3.6% (announces proposed $101 mln investment from Chairman Dr. Vincent Wenyong Shi at $5.25/share), TTM +2.6% (still checking), NURO +2.5% (announces that Premera Blue Cross will pilot the Quell Wearable Pain Relief device within their organization), LCI +2.3% (receives FDA approvals for potassium chloride extended-release capsules & temozolomide capsules), GPRO+2.1% (in symp with peer AMBA upgrade), FL +1.7% (to join S&P 500),WYNN +1.7% (positive industry M&A chatter)
Analyst comments: AMBA +5.8% (upgraded to Overweight at Morgan Stanley)
In reaction to strong earnings/guidance: LEN +3.2%, EHIC +2%, MKC +1.3%
M&A news: ADMP +25.2% (to acquire privately held US Compounding; expected to close in the second quarter of 2016), YHOO +0.5% (wants a deadline of April 11 for bids, according to WSJ)
Other news: KERX +19.8% (announces positive top-line results from phase 3 study of ferric citrate for the treatment of iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease), CNL +13.2% (receives regulatory clearance for sale of co), OHRP +10.5% (reaches agreement on the Special Protocol Assessment with the FDA on the design of the Phase III trial for drug candidate squalamine lactate ophthalmic solution), GALE +8.5% (clinical trial with Neuvax achieves 70 qualifying disease free survival events), OREX +8% (in sympathy with other biotechs this morning), MNOV +4.7% (cont vol pre-mkt), BLRX +4.2% (announces 'positive' top-line results from BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia), NQ +3.6% (announces proposed $101 mln investment from Chairman Dr. Vincent Wenyong Shi at $5.25/share), TTM +2.6% (still checking), NURO +2.5% (announces that Premera Blue Cross will pilot the Quell Wearable Pain Relief device within their organization), LCI +2.3% (receives FDA approvals for potassium chloride extended-release capsules & temozolomide capsules), GPRO+2.1% (in symp with peer AMBA upgrade), FL +1.7% (to join S&P 500),WYNN +1.7% (positive industry M&A chatter)
Analyst comments: AMBA +5.8% (upgraded to Overweight at Morgan Stanley)